Clinical Trial Update: Dose-Escalating Study Of SB-485232 Administered Intravenously Every 28 Days To Adults With Solid Tumors Or Lymphomas [Phase 1]

View source ↗

Summary

A Phase 1 dose-escalation study of SB-485232 given intravenously every 28 days in adults with solid tumors or lymphomas has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Solid Tumors

Drugs mentioned

• SB-485232

Snippet

Sponsor: GlaxoSmithKline | Conditions: Solid Tumor Cancer, Lymphoma | Phase 1 | Status: COMPLETED